Testosterone is a hormone that plays a critical role in developing and maintaining male reproductive tissues. It’s also essential for overall health, well-being, and sexual function. Unfortunately, testosterone levels can drop due to age or certain medical conditions, leading to decreased energy levels, fatigue, loss of libido, erectile dysfunction, and other symptoms. Fortunately, there are treatments available to help restore optimal testosterone levels. One such option is clomiphene citrate therapy.
Enclomiphene citrate (EC) is an oral medication developed by Encouraged Pharmaceuticals as a treatment option for men with low testosterone levels (also known as hypogonadism). It works by stimulating the body’s production of testosterone via the hypothalamus-pituitary-gonadal axis – the main control center responsible for regulating hormones like testosterone in men. EC has been approved by the US Food and Drug Administration (FDA) for use in males aged ≥18 years old with primary or secondary hypogonadism who want to achieve normal serum total testosterone concentrations without increasing estradiol concentrations too high.
How Does Enclomiphene Citrate Work?
Enclomiphene citrate benefits from its mechanism of action, which works on two pathways at once: it stimulates gonadotropin release (LH & FSH), which increases natural testicular testosterone production; at the same time it inhibits negative feedback on LH secretion, thereby further driving up serum T concentrations back into range. By doing this, EC aims to restore physiological functioning while avoiding exogenous synthetic hormones altogether – such as when using injectable forms of T replacement therapy (TRT). This can be particularly beneficial for those with milder cases of low T who may not require more invasive therapies such as injections or topical gels/creams.
Advantages Over Other Treatments
Enclomiphene citrate has many advantages over other treatments for restoring low testosterone levels. For example, it does not increase estrogen levels in the body like some other methods; instead, it helps maintain a healthy balance between free and bound forms of both male sex hormones, minimizing the side effects associated with elevated estrogen levels (e.g. gynecomastia – breast enlargement). In addition, EC provides longer-lasting results than short-acting TRT options such as injections or patches, as patients only need to take one pill a day rather than multiple doses throughout the week/month depending on their needs. Finally, EC may also be safer than alternative treatments because, unlike them, it does not interfere with lipid profiles or liver enzyme tests – key indicators used to assess metabolic health over time.
Risks of using clomiphene citrate
Although EC shows promise as a safe and effective form of restorative TRT, there are risks associated with its use, as there are with any drug therapy option. These include but are not limited to increased risk of prostate cancer, gynecomastia, edema, testicular atrophy, hot flushes, fluid retention, nausea/vomiting, headaches, etc., all potential side effects associated with hormonal manipulation that should be discussed thoroughly before starting any type of treatment regimen. Further research is also needed before we can definitively say whether long-term use could lead to adverse cardiovascular events or serious mental health problems directly related to EC use patterns in patients.
Enclomiphene citrate is an exciting new treatment option that has shown promising results in safely and effectively restoring low testosterone levels in men with symptoms of hypogonadism without having to resort to harsher interventions such as injectables or topical creams/gels. However, further studies are needed before we can make definitive statements about its safety profile, especially when used over longer periods outside of clinical trials so that doctors have accurate information on which to base their decisions about recommending it as part of comprehensive TRT regimens tailored specifically to individual patients’ needs.